Value through Innovation25 November 2015

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive


Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

- For media outside of the US/UK only

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

- For Non-US, Non-UK Media Only

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

- For media outside of the U.S., the UK & Canada only

CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union

- For Non-U.S. and Non-U.K. Media

Boehringer Ingelheim Statement on Hepatitis C drug development

- For media outside of the US, the UK only

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

- For media outside of the U.S., the UK & Canada only

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

- For Non-U.S. and Non-U.K. Media

New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia

- For media outside of the US/UK only

Type 2 Diabetes: Physicians worldwide agree early conversations are crucial in the management of condition

- For Non-US and Non-UK Media

Studies Show Investigational New Insulin Glargine Product from Lilly and Boehringer Ingelheim Similar in Safety and Efficacy to Lantus®

- For Non-U.S. and Non-UK Media

Diabetes: Boehringer Ingelheim and Eli Lilly and Company Alliance to have 43 Presentations Featured at the American Diabetes Association’s 74th Scientific Sessions®

- For Non-US and Non-UK Media

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

- For media outside of the U.S., the UK & Cananda only

EMA accepts marketing authorisation application for nintedanib* in IPF

- For non-US health media only

Boehringer Ingelheim Announces Successful Resolution of FDA Warning Letter


New data show Giotrif® (afatinib) provided more than one year additional survival for lung cancer patients with the most common type of EGFR mutation (del19) compared to chemotherapy

- For Ex-US and Ex-UK Media Only

ASCO 2014: Boehringer Ingelheim to present latest oncology research, including overall survival results for Giotrif® (afatinib) in advanced NSCLC

- For Ex-US and Ex-UK Media Only

Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation


Type 2 Diabetes: European Commission approves Jardiance® (empagliflozin)

- For Non-U.S. and Non-U.K. Media